European Journal of Clinical Pharmacology最新文献

{"title":"Understanding attitudes towards psychiatric medications: a comparative study of patients, healthcare professionals, and general population perspectives.","authors":"Seda Yavuz, Yavuz Yılmaz, Erdi Bahadır","doi":"10.1007/s00228-025-03879-7","DOIUrl":"https://doi.org/10.1007/s00228-025-03879-7","url":null,"abstract":"<p><strong>Background: </strong>In recent years, with the increasing challenges in living conditions, there has been a rise in individuals seeking psychiatric support. This situation may lead to changes in attitudes and perceptions towards psychiatric medication treatments.</p><p><strong>Aim: </strong>This study aims to examine the attitudes of stable psychiatric patients, healthcare professionals, and the general population toward psychiatric medication treatments.</p><p><strong>Method: </strong>The study included 311 stable psychiatric patients, 200 healthcare professionals, and 274 participants from the general population. Participants were administered a data form that questioned sociodemographic and clinical characteristics, the Drug Attitude Inventory-10, and the Beliefs about Medicines Questionnaire.</p><p><strong>Results: </strong>The study reveals significant differences in attitudes towards medication among stable psychiatric patients, non-psychiatric healthcare professionals, and the general population. Stable psychiatric patients tend to have a stronger belief in the positive effects of medication and are more likely to internalize medications in their daily lives. However, this group experiences side effects more intensely compared to other groups. Healthcare professionals maintain a balanced stance regarding the benefits and side effects of medications, while the general population exhibits a more negative attitude towards medications and expresses greater concern about the addictive potential of these drugs.</p><p><strong>Conclusion: </strong>Considering these differences may contribute to more effective management of treatment processes and improve attitudes toward medications.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis and systematic review of the first Trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer.","authors":"Jue Wang, Shengyou Lin, Jialin Zhang, Jingyang Su","doi":"10.1007/s00228-025-03876-w","DOIUrl":"https://doi.org/10.1007/s00228-025-03876-w","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the effectiveness and safety of sacituzumab govitecan in metastatic breast cancer (MBC), we performed a meta-analysis of randomized controlled trials comparing sacituzumab govitecan with chemotherapy.</p><p><strong>Methods: </strong>We systematically searched multiple databases for relevant studies. Primary outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). Data were analyzed using RevMan 5.3 software.</p><p><strong>Results: </strong>Three studies were included after rigorous screening and quality assessment. Compared with chemotherapy, sacituzumab govitecan significantly prolonged PFS [HR 0.57; 95% CI 0.43, 0.77; P = 0.0002], improved OS [HR 0.64; 95% CI 0.48, 0.85; P = 0.002], and increased ORR [RR 2.84; 95% CI 1.27, 6.37; P = 0.01]. However, sacituzumab govitecan was associated with higher incidence of AEs (P < 0.00001).</p><p><strong>Conclusion: </strong>In this study, sacituzumab govitecan demonstrated improved PFS and OS compared to chemotherapy regimens in patients with MBC. Further research is required to validate its broad applicability and long-term treatment stability.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosing prediction of valproic acid in pediatric patients with epilepsy: population pharmacokinetic model or machine learning model?","authors":"Jingcheng Chen, Jiacheng Wang, Kai Li, Yujie Wu, Ziqian Wang, Jin Guo, Zhigang Zhao, Weixing Feng, Shenghui Mei","doi":"10.1007/s00228-025-03874-y","DOIUrl":"https://doi.org/10.1007/s00228-025-03874-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study develops and compares population pharmacokinetics (PopPK) models and machine learning methods, including neural networks, to predict steady-state trough concentrations in pediatric patients and provide improved dosing recommendations.</p><p><strong>Methods: </strong>Valproic acid concentration data were collected from 490 pediatric epilepsy patients treated at Beijing Tiantan Hospital and Beijing Children's Hospital. We developed predictive models employing PopPK, maximum a posteriori Bayesian (MAPB), multiple linear regression (MLR), machine learning (including Random Forest, XGBoost, and LightGBM for feature selection), and neural network techniques. The predictive accuracy of these models was then rigorously tested through external validation using the independent dataset from Beijing Children's Hospital. Upon identifying the optimal model, dosing regimens for various clinical scenarios were derived and presented.</p><p><strong>Results: </strong>Under the same dataset modeling conditions, the original PopPK models showed limited predictive performance. Transforming these models into multiple linear regression enhanced prediction accuracy. Moreover, when prior data was available, the MAPB method significantly boosted prediction performance. Machine learning and neural networks showed higher accuracy, with neural networks achieving an F₃₀ value above 80%.</p><p><strong>Conclusion: </strong>This study explored model optimization strategies and compared machine learning and neural network models alongside traditional PopPK. It introduced an advanced method to predict drug concentrations and stable trough dosing regimens in pediatric epilepsy treatment, reducing the need for frequent, invasive blood tests in TDM. These improvements enhanced the efficacy and safety of valproic acid therapy for children, supporting the development of personalized treatment plans.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pentoxifylline uses in inner ear diseases.","authors":"Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Mufreh Amin, Rovan Ahmed Rouby, Ghalia Aljarrah, Dalia Gamal Elnady, Ahmed Samir, Thoria Ibrahim Essa Ghanm, Zahraa Natheer Bhaya, Abdallah Altarras, Fares Abdelsalam, Mohamed Yasser, Mahmoud Samir, Mostafa Ramzi Shiha","doi":"10.1007/s00228-025-03844-4","DOIUrl":"10.1007/s00228-025-03844-4","url":null,"abstract":"<p><strong>Background: </strong>Labyrinth or the inner ear consists of the cochlea (for hearing) and vestibular system (for balance), with disorders affecting hearing, balance, or both, and symptomatology including hearing loss, tinnitus, and vertigo. Regulatory-approved medications for inner ear diseases are rare worldwide relative to the frequency of those diseases. There are no FDA-approved medications for any inner ear disease. This is due to multiple reasons, including the lack of conclusive evidence for various drugs that have been investigated. We aim to contribute to the review endeavor by addressing pentoxifylline (PTX), a medication that has been studied for cochlear and vestibular disorders, yet its efficacy and safety have not been systematically reviewed in a publication.</p><p><strong>Methods: </strong>More than a dozen databases from around the globe were systematically searched, including PubMed, EMBASE, Scopus, Web of Science, Cochrane/CENTRAL, ScienceDirect, Google Scholar, Europe PMC, ICTRP, ClinicalTrials.gov, EU-CTR, PsycInfo, LILACS, WPRIM, IBECS, SciELO, CNKI, VIP, and Wanfang, to methodically compile experimental and analytical studies. Search results are up to January 2025. This work focused on workable reports in which PTX had distinct or attributable results and organized them into overarching categories of vertigo, hearing loss, and tinnitus.</p><p><strong>Results: </strong>Forty studies, including 15 randomized controlled trials (RCTs), were included. Each condition was addressed in seven RCTs, with some overlap. Studies on inner ear vertigo reported significant outcomes for PTX. A large proportion of the literature involved idiopathic sudden sensorineural hearing loss (ISSNHL), but its results were mixed. Studies on tinnitus suggest that PTX has similar efficacy to Ginkgo biloba extract and corticosteroids, two of the most prescribed medications. Adverse events were generally mild and rarely necessitated discontinuation.</p><p><strong>Conclusion: </strong>Pentoxifylline could improve inner ear vertigo and tinnitus. In ISSNHL, results are inconsistent in the context of spontaneous recovery rates, albeit leaning toward ineffectiveness. Over a variety of regimens, it sustained good safety. The rigor and designs of the reports could not produce robust recommendations.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"955-999"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Signals from randomized clinical trials predicting hepatotoxicity of flupirtine: systematic review.","authors":"Mahir Fidahic, Emilija Lozo Vukovac, Ewa Balkowiec-Iskra, Darko Krnic, Adriana Andric, Zeljana Margan Koletic, Livia Puljak","doi":"10.1007/s00228-025-03840-8","DOIUrl":"10.1007/s00228-025-03840-8","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to systematically review clinical trials evaluating the flupirtine to identify any biochemical or clinical indicators that could signal serious hepatotoxicity.</p><p><strong>Methods: </strong>This systematic review included randomized controlled trials (RCTs) evaluating flupirtine-containing medicines for any clinical condition. Trials involving any population, comparator, or outcome were considered eligible for inclusion. A comprehensive search was conducted in Embase, MEDLINE, and CENTRAL from their inception until August 14, 2023. The risk of bias (RoB) in the included trials was assessed using Cochrane's 2011 RoB tool. Due to the heterogeneity of the included trials, a meta-analysis could not be performed.</p><p><strong>Results: </strong>A total of 35 trials published between 1983 and 2022 were included in this systematic review, with 1408 participants receiving flupirtine. Only five trials reported any data related to liver function tests. Among these, four trials documented transient, asymptomatic liver abnormalities that returned to normal after the trial period, while one trial was prematurely terminated. One trial reported normal liver test results in all participants. Of the three trials published after 2018, only one acknowledged the withdrawal of flupirtine from the European market. The majority of risk of bias (RoB) domains were classified as having an unclear risk of bias.</p><p><strong>Conclusion: </strong>Published RCTs did not report any evidence of serious hepatotoxicity associated with flupirtine based on the available biochemical or clinical data. However, liver function test results were reported in only 5 out of 35 included trials. Published RCTs are not reliable information about flupirtine-related hepatotoxicity.</p><p><strong>Registration: </strong>Protocol was published in PROSPERO (CRD42018085123).</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1043-1054"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of a medication discrepancy management platform in reducing medication discrepancy and influencing factors among elderly patients with polypharmacy.","authors":"Jingyan Song, Jie Huang, Jian Mao, Jing Cao, Qinghua Zhao","doi":"10.1007/s00228-025-03831-9","DOIUrl":"10.1007/s00228-025-03831-9","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the impact of a medication discrepancy management platform on reducing medication discrepancies among elderly patients with polypharmacy and to analyze influencing factors.</p><p><strong>Methods: </strong>A total of 110 elderly polypharmacy patients were divided into a control group and an observation group using a random number method, each with 55 participants. The control group received routine management, while the observation group utilized a medication discrepancy management platform. Medication knowledge and adherence before and after intervention were compared between the two groups. Reasons and types of medication discrepancies were statistically analyzed. Patients were divided into a non-discrepancy group and a discrepancy group, with multivariate logistic regression used to analyze factors influencing medication discrepancies among elderly patients with polypharmacy.</p><p><strong>Results: </strong>Utilizing a medication discrepancy management platform significantly improved medication knowledge and adherence among elderly patients (P < 0.05). A total of 34 patients (30.91%) experienced at least one medication discrepancy within one-week post-discharge, primarily involving decreased frequency, missed doses, reduction in medication types, and medication substitution. Multivariate logistic regression analysis showed that the use of the medication discrepancy management platform, caregiver involvement, and prescribed discharge medications (7-8 types or ≥ 9 types) were independent factors influencing medication discrepancies in elderly patients (P < 0.05).</p><p><strong>Conclusion: </strong>Using a medication discrepancy management platform can effectively reduce medication discrepancies in elderly patients with polypharmacy and improve elderly patients' adherence to medication. Expanding the platform's use can enhance discharge guidance quality and ensure medication safety.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1017-1027"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a visualization platform for ADR query and analysis: an example of severe skin adverse reactions caused by sulfonylureas.","authors":"Hui-Min Yu, Ya-Min Huang, Jian Xiao, Lu Zhang, Hang-Xing Huang, Ling Huang, Jing-Yang Li, Xin-Qiong Huang","doi":"10.1007/s00228-025-03842-6","DOIUrl":"10.1007/s00228-025-03842-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop a visualization platform for querying and analysing data from the FDA Adverse Event Reporting System (FAERS) to support the efficient collection, review, and analysis of adverse drug reactions (ADRs) for pharmacovigilance.</p><p><strong>Methods: </strong>Data acquisition, cleaning, and integration processes were conducted to prepare FAERS data for analysis. The platform was designed with key functionalities, including multi-condition query, drug and ADR query, primary ID query, and interactive visualizations. Usability was demonstrated through a case study investigating the association between sulfonylureas and serious skin ADRs. Additionally, the platform's accuracy was validated by comparing its outputs with manually retrieved and visualized data using a separate test case involving aspirin and tremor.</p><p><strong>Results: </strong>The platform provides an interface with advanced query and visualization features, enabling users to efficiently retrieve, analyse, and visualize ADR data. Usability was illustrated by dynamically exploring FAERS data to identify safety signals for sulfonylureas and serious skin ADRs. The validation process confirmed the platform's reliability by showing consistent results with manually processed data, demonstrating its potential to streamline PV workflows and improve data interpretation.</p><p><strong>Conclusion: </strong>The visualization platform represents a novel and practical tool for pharmacovigilance research. By offering intuitive data query and analysis capabilities, the platform supports drug safety monitoring and promotes the development of pharmacovigilance practices.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1055-1067"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed psychotropic toxicity after switching from nevirapine to bictegravir: the role of enzyme de-induction in people with HIV and polypharmacy.","authors":"Giacomo Pozza, Andrea Giacomelli, Annalisa Ridolfo, Maria Vittoria Cossu, Andrea Gori, Dario Cattaneo, Cristina Gervasoni","doi":"10.1007/s00228-025-03873-z","DOIUrl":"https://doi.org/10.1007/s00228-025-03873-z","url":null,"abstract":"","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring risk assessment tools for medicine-related problems among culturally and linguistically diverse patients in Australia: a systematic review.","authors":"Rawan Sawalha, Sarah Al-Samawy, Zeyad Mahmoud, Chloe Tadorian, Christopher Levi, Neil Spratt, Hassan Hosseinzadeh, Beata Bajorek","doi":"10.1007/s00228-025-03845-3","DOIUrl":"10.1007/s00228-025-03845-3","url":null,"abstract":"<p><strong>Purpose: </strong>This review evaluated publications that described medicine risk assessment tools developed or adapted for use in Australia to assess risks associated with medicine-related problems (MRPs). It examined whether these tools considered cultural background as a crucial risk factor for MRPs and whether clinical guidelines provided tailored recommendations for Culturally and Linguistically Diverse (CALD) patients.</p><p><strong>Methods: </strong>A systematic search was conducted in Web of Science, Scopus, CINHAL, EMBASE, PubMed/Medline and Google Scholar (January 1985-November 2024). The review included publications on the development or validation of medicine risk assessment tools for MRPs in Australia, as well as clinical guidelines relevant to managing diseases classified as National Health Priority Areas (NHPAs).</p><p><strong>Results: </strong>Sixteen publications on thirteen medication risk assessment tools and thirteen publications on twelve clinical therapeutic guidelines were included. Risk factors varied widely and were categorised into four groups: patient-related (e.g. age, cognitive status), disease-related (e.g. comorbidities), medicine-related (e.g. polypharmacy), and health services-related (e.g. re-hospitalisations). Only one tool considered CALD background as a risk factor for MRPs. Although some tools acknowledged non-adherence or communication issues, they did not systematically address underlying cultural or linguistic factors. Clinical guidelines primarily focused on self-management and providing information in CALD patients' first language, with some encouraging interpreter use.</p><p><strong>Conclusion: </strong>Medicine risk assessment tools lack consistent frameworks, and CALD backgrounds are largely overlooked as a key demonstrated risk factor for MRPs. Future research should develop inclusive tools and clinical guidelines incorporating cultural and linguistic factors. Policymakers and healthcare practitioners should refine these tools to improve medication safety and achieve equitable healthcare outcomes for CALD populations.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"913-938"},"PeriodicalIF":2.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Relevant errors in a systematic review and network meta-analysis evaluating the efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia.","authors":"Christoph U Correll, David Rowe, Rinat Ribalov, Verena Ramirez Campos, Marco Solmi","doi":"10.1007/s00228-025-03826-6","DOIUrl":"10.1007/s00228-025-03826-6","url":null,"abstract":"","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1099-1101"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12152080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}